Biosafety assays for the diagnosis and prediction of drug related complement pat...
Biosafety assays for the diagnosis and prediction of drug related complement pathology
The objective of this Twinning project is to significantly strengthen the research in SEMMELWEIS EGYETEM in the smart specialization area of Hungary bio-medicine, medical technologies, and biotechnologies with application to immun...
ver más
31/08/2023
SEMMELWEIS UNIVERS...
900K€
Presupuesto del proyecto: 900K€
Líder del proyecto
SEMMELWEIS EGYETEM
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Biosafety
Duración del proyecto: 37 meses
Fecha Inicio: 2020-07-06
Fecha Fin: 2023-08-31
Líder del proyecto
SEMMELWEIS EGYETEM
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
900K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The objective of this Twinning project is to significantly strengthen the research in SEMMELWEIS EGYETEM in the smart specialization area of Hungary bio-medicine, medical technologies, and biotechnologies with application to immune- and biosafety assays through building an up-rising connections with internationally leading research institutions, which represent centers of excellence in the design, testing and clinical applications of a wide class of Immunotherapeutics, with focus on infusion reactions (IRs). IRs are complex, immune-mediated side effects, also known as hypersensitivity reactions (HSRs), that can occur upon intravenous infusion of pharmaceuticals, leading to severe and sometimes life-threatening conditions in patients. Regulatory guidance on the assessment of infusion hypersensitivity has been published recently for the case of generic liposome production. Hemocompatibility (blood safety) testing for medical devices is requested by EMA and FDA since many years. However, regarding the potential of new pharmaceuticals causing allergies remains a significant challenge for the industry during nonclinical development as no established safety biomarker nor meaningful, validated animal models are available up to date and this will be addressed in the BIOSAFETY project.